Literature DB >> 33881148

Major cardiovascular events at 5 years in surgical versus percutaneous revascularization for left main stem disease: an updated meta-analysis.

Stefano Urso1, Rafel Sadaba2, Eliú Nogales3, Jesús María González4, María Ángeles Tena1, Federico Paredes1, Miguel González-Barbeito1, Francisco Portela1.   

Abstract

The aim of the present study was to analyse the incidence of major adverse cardiovascular events in patients undergoing either coronary artery bypass grafting (CABG) or percutaneous coronary intervention with drug-eluting stents for left main stem disease. Five manuscripts publishing 5-year results of 4 trials (SYNTAX, PRECOMBAT, NOBLE and EXCEL) were included. Overall meta-analysis with inclusion of the 5-year results from the EXCEL trial using the protocol definition for myocardial infarction showed that CABG is associated with a significant reduction in the risk of major adverse cardiovascular events (MACE) (risk ratio = 0.74; 95% confidence interval = 0.68-0.80). When the universal definition was used to define myocardial infarction in the EXCEL trial, the analysis demonstrated a larger benefit of coronary surgery in terms of reduction in the risk of MACE (risk ratio = 0.70; 95% confidence interval = 0.63-0.76). Non-significant differences were detected in terms of risk of overall mortality, cardiac mortality or stroke. In conclusion, this meta-analysis shows that CABG significantly reduces the risk of MACE in patients with left main stem disease. The inclusion of the 5-year results of the EXCEL trial using third universal definition amplifies the benefit of CABG over percutaneous coronary intervention.
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Coronary artery bypass grafting; Drug-eluting stent; Left main disease; Meta-analysis; Percutaneous coronary intervention

Mesh:

Year:  2021        PMID: 33881148      PMCID: PMC8906685          DOI: 10.1093/icvts/ivaa301

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  9 in total

1.  Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias.

Authors:  Karsten Knobloch; Uzung Yoon; Peter M Vogt
Journal:  J Craniomaxillofac Surg       Date:  2010-12-09       Impact factor: 2.078

2.  Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial.

Authors:  Niels R Holm; Timo Mäkikallio; M Mitchell Lindsay; Mark S Spence; Andrejs Erglis; Ian B A Menown; Thor Trovik; Thomas Kellerth; Gintaras Kalinauskas; Lone Juul Hune Mogensen; Per H Nielsen; Matti Niemelä; Jens F Lassen; Keith Oldroyd; Geoffrey Berg; Peteris Stradins; Simon J Walsh; Alastair N J Graham; Petter C Endresen; Ole Fröbert; Uday Trivedi; Vesa Anttila; David Hildick-Smith; Leif Thuesen; Evald H Christiansen
Journal:  Lancet       Date:  2019-12-23       Impact factor: 79.321

3.  Third universal definition of myocardial infarction.

Authors:  Kristian Thygesen; Joseph S Alpert; Allan S Jaffe; Maarten L Simoons; Bernard R Chaitman; Harvey D White
Journal:  Glob Heart       Date:  2012-09-26

4.  Randomized Trial of Stents Versus Bypass Surgery for Left Main Coronary Artery Disease: 5-Year Outcomes of the PRECOMBAT Study.

Authors:  Jung-Min Ahn; Jae-Hyung Roh; Young-Hak Kim; Duk-Woo Park; Sung-Cheol Yun; Pil Hyung Lee; Mineok Chang; Hyun Woo Park; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Suk Jung Choo; CheolHyun Chung; JaeWon Lee; Do-Sun Lim; Seung-Woon Rha; Sang-Gon Lee; Hyeon-Cheol Gwon; Hyo-Soo Kim; In-Ho Chae; Yangsoo Jang; Myung-Ho Jeong; Seung-Jea Tahk; Ki Bae Seung; Seung-Jung Park
Journal:  J Am Coll Cardiol       Date:  2015-03-15       Impact factor: 24.094

5.  Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease.

Authors:  Gregg W Stone; A Pieter Kappetein; Joseph F Sabik; Stuart J Pocock; Marie-Claude Morice; John Puskas; David E Kandzari; Dimitri Karmpaliotis; W Morris Brown; Nicholas J Lembo; Adrian Banning; Béla Merkely; Ferenc Horkay; Piet W Boonstra; Ad J van Boven; Imre Ungi; Gabor Bogáts; Samer Mansour; Nicolas Noiseux; Manel Sabaté; Jose Pomar; Mark Hickey; Anthony Gershlick; Pawel E Buszman; Andrzej Bochenek; Erick Schampaert; Pierre Pagé; Rodrigo Modolo; John Gregson; Charles A Simonton; Roxana Mehran; Ioanna Kosmidou; Philippe Généreux; Aaron Crowley; Ovidiu Dressler; Patrick W Serruys
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

6.  Five-year outcomes in patients with left main disease treated with either percutaneous coronary intervention or coronary artery bypass grafting in the synergy between percutaneous coronary intervention with taxus and cardiac surgery trial.

Authors:  Marie-Claude Morice; Patrick W Serruys; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; James W Choi; Witold Ruzyllo; Grzegorz Religa; Jian Huang; Kristine Roy; Keith D Dawkins; Friedrich Mohr
Journal:  Circulation       Date:  2014-04-03       Impact factor: 29.690

7.  Levosimendan versus placebo in cardiac surgery: a systematic review and meta-analysis.

Authors:  María Ángeles Tena; Stefano Urso; Jesús María González; Luis Santana; Rafael Sadaba; Paula Juarez; Leonor González; Francisco Portela
Journal:  Interact Cardiovasc Thorac Surg       Date:  2018-11-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.